ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Reviewing the possible connection between cerebral amyloid angiopathy and blood-brain barrier integrity in Down syndrome.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.Expert review of neurotherapeutics · 2026Review
- Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.Neuromolecular medicine · 2026Article
- Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Reviewing the possible connection between cerebral amyloid angiopathy and blood-brain barrier integrity in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Individuals with Down syndrome (DS) have a higher risk of developing cerebral amyloid angiopathy (CAA), primarily because of the excessive production of amyloid beta (Aβ). However, the consequences of CAA on blood-brain barrier (BBB) integrity and the neurovascular unit (NVU) are still not well understood. Systematic search was conducted on PubMed using 12 targeted keywords related to CAA, BBB, and the NVU in combination with DS. Additional sources were identified and the research gap validated using Consensus and ChatGPT-assisted literature screening. Individuals with DS are vulnerable to cerebrovascular conditions across their lifespan. Despite pronounced Aβ pathology, CAA appears less frequent than in cases with microduplication of the APP locus, suggesting distinct vascular dynamics potentially influenced by chromosome 21 genes. Limited direct evidence on BBB integrity in DS highlights the need for mechanistic and longitudinal studies. DS offers a unique lens for exploring cerebrovascular resilience and CAA pathogenesis. HIGHLIGHTS: Down syndrome (DS) individuals overexpressing amyloid precursor protein (APP) are at risk for cerebral amyloid angiopathy (CAA) and lobar microbleeds. CAA is less severe in DS compared to APP microduplication (APPdup) cases. Intracerebral hemorrhage (ICH) is less common in DS than in APPdup cases. DS may have protective mechanisms against CAA and ICH involving BBB function. Few longitudinal studies examine BBB permeability in DS across the lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.